Betaglue takes radiotherapy inside solid tumours: first patient treated

• The first clinical results have shown that BAT-90 innovative radiotherapy platform makes it possible to treat only the area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatment efficacy and patient safety
• CEO/CMO, Dr. Antonino Amato, said: "The confirmation in this first patient of the previous findings from the pre-clinical studies with BAT-90 opens up tremendous perspectives for therapeutic nuclear medicine in oncology, which will hopefully lead to improved outcomes and better quality of life for patients affected by several types of cancer. The targeted and localised BAT-90 treatment will strengthen even more the concept of precision medicine in radiotherapy"

Milan, July 11, 2022- BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, announces today that the first patient has been treated in a clinical trial with BAT-90, the compan/s cancer radiotherapy platform.

The patient, suffering from liver cancer (hepatocarcinoma), was treated with BAT-90, a technology involving the delivery of Yttrium-90-labelled microspheres through a proprietary device straight into the tumour, where they are retained by a fast-curing, biocompatible glue. Two months after injection, clinical results confirmed that BetaGlue Technologies` radiotherapy platform remains localized only in the area where the tumour is located, thus not exposing surrounding tissues or organs to unnecessary radiations.

BAT-90
BAT-90 (`Beta Ablation Therapy with Yttrium-90`) consists of a p radiation-emitting biocompatible matrix, delivered to patients via percutaneous injection: the Yttrium-90-labelled microspheres present inside the matrix are injected into the tumour and, as the carrier takes only 120 seconds to reach full polymerisation, they are retained exclusively in the injected area. This prevents the microspheres from spreading to surrounding tissues or organs, so as to release their radiation energy only to the target tumour. In this way, a very low radioactive dose is needed, much lower than the one used with conventional radio-metabolic treatments, thus enhancing treatment efficacy and patient safety.

Benefits
BAT-90 opens up important horizons in oncology, bringing benefits to both patients and the healthcare systems. Indeed, BAT-90 is a therapeutic nuclear medicine solution that is extremely precise (it only targets the tumour area), personalised (calibrated to the patient`s clinical situation), rapid (a single injection reaching full polymerisation in just a few minutes) and safe (the radiation energy is released where needed, avoiding exposure of surrounding tissues and organs, thus minimizing any risk to either patients or healthcare professionals).